Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies that will be focused on taking biotech companies public.
MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here’s everything you need to know about this billion dollars deal.
There were seven initial public offerings (IPOs) for biotech companies in the month of May. Here’s a look.
The company, which isn’t expected to enter the clinic until possibly in 2022, is working to make cell therapies work in solid tumors.
The additional 100 people will be placed in Seattle, San Francisco, and Cambridge, Mass. by the end of the year.
The UK’s Competition and Markets Authority (CMA) will determine if the deal is anti-competitive.
Janux plans to use the funds raised from the IPO to submit four Investigational New Drug applications to the U.S. FDA in the first half of 2022.
Less than two weeks after Ginkgo Bioworks announced a merger with SPAC Soaring Eagle Acquisition Corp., it announced a collaboration partnership with Biogen.
Centred connects travelers to leading and emerging wellness brands in over 200 cities worldwide, utilizing a vertically integrated platform with an app, website, physical locations, e-commerce, health and wellness, and loyalty programs.
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.